EGFR Mutation Analysis by ARMS PCR for Stratifying Patients with NSCLC

This analysis seeks to identify any EGFR gene mutations linked to non-small cell lung cancer (NSCLC). An important platform for the identification of the genes responsible for NSCLC is the Amplification Refractory Mutation System (ARMS), an enhanced version of the polymerase chain reaction (PCR).

It often advances and metastasizes more gradually than small-cell lung cancer. Adenocarcinoma, squamous cell carcinoma (SCC), and giant cell carcinoma are the three subtypes of NSCLC.

Since stage greatly influences the type of treatment chosen, patients with NSCLC undergo a thorough staging workup to determine the degree of the disease.

What does the ARMS PCR EGFR Mutation Analysis for stratifying patients with NSCLC Test entail?

This examination is done on the patient's tumor tissue who has Non-Small Cell Lung Cancer. . The patient will receive therapy for lung cancer on the findings. Since obtaining tumor tissue by a biopsy hurts the patient, blood plasma is used in this test in place of tumor tissue for analysis.

Stratifying individuals with NSCLC using ARMS PCR for EGFR Mutation Analysis:

These patients' plasma samples will be taken to conduct the testing.

This test will be performed on a patient who received EGFR TKI therapy but later developed resistance to the treatment.

Benefits of EGFR Mutation Analysis by ARMS PCR to classify NSCLC patients:

The goal of the test is to find the mutations that stop medications from acting on the EGFR gene to reduce cancer.

• Since there is no requirement for tumor tissue with this technology, the patient won't experience any discomfort during the biopsy.

Method for stratifying NSCLC patients using ARMS PCR EGFR Mutation Analysis Test:

• The patient's plasma samples will be examined using the polymerase chain reaction (PCR) and ARMS (amplification refractory mutation systems) methods.
• The test will only be conducted in accredited medical laboratories.
• The targeted therapy samples collected before and after administration are examined in the laboratory to find the EGFR gene resistance mutation.
• The patient will receive additional treatment by this.

Limitations of the ARMS PCR EGFR Mutation Analysis for Patients with NSCLC Test:

LabCorp created this test and determined its performance parameters.